

Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium

A. Venkatesan,¹ A. R. Tunkel,² K. C. Bloch,^{3,4} A. S. Luring,⁵ J. Sejvar,⁶ A. Bitnun,⁷ J-P. Stahl,⁸ A. Mailles,⁹ M. Drebot,¹⁰ C. E. Rupprecht,¹¹ J. Yoder,¹² J. R. Cope,¹² M. R. Wilson,^{13,14} R. J. Whitley,^{15,16,17,18} J. Sullivan,¹⁹ J. Granerod,²⁰ C. Jones,^{21,22} K. Eastwood,²³ K. N. Ward,^{20,24} D. N. Durrheim,^{25,26} M. V. Solbrig,²⁷ L. Guo-Dong,²⁸ and C. A. Glaser,²⁹ on behalf of the International Encephalitis Consortium

¹Johns Hopkins Encephalitis Center, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland; ²Warren Alpert Medical School of Brown University, Providence, Rhode Island; Departments of ³Medicine (Infectious Diseases) and ⁴Preventive Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; ⁵Division of Infectious Diseases, Department of Medicine, University of Michigan Medical School, Ann Arbor; ⁶Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; ⁷Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada; ⁸Infectious Diseases Department, CHU and University 1, Grenoble, France; ⁹Department Infectious Diseases, French Institute for Public Health Surveillance, Saint-Maurice, France; ¹⁰National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba; ¹¹Global Alliance For Rabies Control, Manhattan, Kansas; ¹²Waterborne Disease Prevention Branch, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Departments of ¹³Neurology and ¹⁴Medicine, Boston University School of Medicine, Massachusetts; Departments of ¹⁵Pediatrics, ¹⁶Microbiology, ¹⁷Medicine, and ¹⁸Neurosurgery, University of Alabama at Birmingham; ¹⁹Central Clinical School, University of Sydney, New South Wales, Australia; ²⁰Virus Reference Department, Public Health England, London; ²¹Sydney Emerging Infectious Diseases and Biosecurity Institute, and ²²The Children's Hospital Westmead Clinical School, University of Sydney, New South Wales, and ²³Hunter New England Population Health, Wallsend, New South Wales, Australia; ²⁴Division of Infection and Immunity, University College London, England; ²⁵University of Newcastle, and ²⁶Hunter Medical Research Institute, Wallsend, New South Wales, Australia; ²⁷Department of Medicine (Neurology) and Medical Microbiology, University of Manitoba, Winnipeg, Canada; ²⁸Department of Viral Encephalitis and Arbovirus, State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China; and ²⁹Division of Communicable Disease Control, California Department of Public Health, Richmond

Background. Encephalitis continues to result in substantial morbidity and mortality worldwide. Advances in diagnosis and management have been limited, in part, by a lack of consensus on case definitions, standardized diagnostic approaches, and priorities for research.

Methods. In March 2012, the International Encephalitis Consortium, a committee begun in 2010 with members worldwide, held a meeting in Atlanta to discuss recent advances in encephalitis and to set priorities for future study.

Results. We present a consensus document that proposes a standardized case definition and diagnostic guidelines for evaluation of adults and children with suspected encephalitis. In addition, areas of research priority, including host genetics and selected emerging infections, are discussed.

Conclusions. We anticipate that this document, representing a synthesis of our discussions and supported by literature, will serve as a practical aid to clinicians evaluating patients with suspected encephalitis and will identify key areas and approaches to advance our knowledge of encephalitis.

Keywords. encephalitis; guidelines; viral; autoimmune; host genetics.

Encephalitis results in substantial morbidity and mortality worldwide. Specific etiologies are identified in <50% of cases, in part due to lack of consensus on case

definitions and standardized diagnostic approaches. Advances in encephalitis are hampered by the rarity

Received 10 May 2013; accepted 3 July 2013.

Correspondence: Arun Venkatesan, MD, PhD, Johns Hopkins University School of Medicine, 600 N Wolfe St, Meyer 6-113, Baltimore, MD 21287 (avenkat2@jhmi.edu).

Clinical Infectious Diseases

© The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

DOI: 10.1093/cid/cit458

and heterogeneity of cases, highlighting the need for a collaborative international approach. In March 2012, the International Encephalitis Consortium held a meeting in Atlanta to discuss recent advances in encephalitis and to set priorities for future study. This consortium is an ad-hoc committee begun in 2010 with members from the Americas, Europe, Australia, Africa, and Asia. The mission of the consortium is to advance knowledge of the causes, diagnostic strategies, treatment, and outcome of encephalitis, and to implement interventions based upon this knowledge. Topics discussed at the meeting included: (1) standardization of a case definition for encephalitis, (2) development of practical diagnostic algorithms for evaluation of patients, (3) the role of host genetics in encephalitis, and (4) priorities for the study of selected emerging infectious diseases. Here we present a consensus document that synthesizes our discussions and recent literature, with the goals of aiding clinicians evaluating patients with suspected encephalitis and of identifying priorities and approaches to advance knowledge of encephalitis.

PRIORITY 1: CASE DEFINITION

Encephalitis is defined as inflammation of the brain parenchyma associated with neurologic dysfunction [1]. Although pathologic examination and testing of brain tissue is considered to be the “gold standard” diagnostic test for this syndrome, this is rarely done premortem due to potential morbidity associated with an invasive neurosurgical procedure. In the absence of pathologic confirmation, encephalitis has previously been defined on the basis of selected clinical, laboratory, electroencephalographic, and neuroimaging features [2–7] (Supplementary Table 1). One of the most widely used case definitions for encephalitis, developed by the Brighton Collaboration Encephalitis Working Group [6], standardizes reporting of post-immunization neurologic events. However, whether this definition is applicable to the diagnosis of infectious or autoimmune encephalitis, as well as the relative sensitivity and specificity of the varying levels of diagnostic accuracy of this definition, is unknown.

Further complicating development of a cohesive case definition for encephalitis is the clinical overlap between encephalitis and encephalopathy, terms often used interchangeably in the literature but that may represent distinctive pathophysiologic processes. Encephalopathy refers to a clinical state of altered mental status, manifesting as confusion, disorientation, behavioral changes, or other cognitive impairments, with or without inflammation of brain tissue. Encephalopathy without inflammation can be triggered by a number of metabolic or toxic conditions but may also be associated with specific infectious agents, such as *Bartonella henselae* [8–10] or influenza virus [11–14].

In contrast, encephalitis is characterized by brain inflammation as a consequence of direct infection of the brain parenchyma, a post-infectious process such as acute disseminated encephalomyelitis (ADEM) [6, 15], or a noninfectious condition such as anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis [16, 17]. In the absence of pathologic evidence of brain inflammation, an inflammatory response in the cerebrospinal fluid (CSF) or the presence of parenchymal abnormalities on neuroimaging are often used as surrogate markers of brain inflammation. However, encephalitis can occur without significant CSF pleocytosis or demonstrable neuroimaging abnormalities [18–21].

Development of a standardized case definition for encephalitis and encephalopathy of presumed infectious etiology is important for epidemiological surveillance, clinical research, and outbreak investigations. Implementation of a case definition broadly applicable to regions with substantially different resources and surveillance capacities facilitates investigation of newly recognized or emerging causes of encephalitis. Because of the significant clinical overlap between encephalitis (infectious and noninfectious) and encephalopathy of presumed infectious etiology, the case definition is formulated to capture both syndromes.

Several caveats must be recognized regarding the proposed case definition. First, alteration in mental status is a required component (Major criterion; Table 1). It is recognized that some infections or conditions related to infections may cause central nervous system (CNS) dysfunction without affecting consciousness (eg, post-varicella cerebellar ataxia [22]), and our case definition would not capture these entities. Second, there is no restriction on the maximum duration of altered mental status, and therefore both acute causes of encephalitis as well as more subacute or chronic infectious conditions such as those caused by fungi or mycobacteria would meet the case definition. Third, several additional criteria are required to substantiate a diagnosis of encephalitis (Minor criteria; Table 1). Finally, the syndromic definition is viewed to be complementary to the diagnostic testing algorithm (see Priority 2: Diagnostic Algorithm section and Tables 2 and 3). Thus, while identification of an infection with an organism that is strongly associated with encephalitis from an appropriate biologic sample would confirm a clinical diagnosis of encephalitis, failure to identify a pathogen, as has been reported in >50% of cases of presumed encephalitis in some series [1, 5], would not exclude the diagnosis.

Summary

The proposed definition of encephalitis and encephalopathy of presumed infectious etiology was developed based on consensus expert opinion and review of available literature. We anticipate that validation using existing cohorts as well as additional prospective studies will be crucial in refining and improving the case definition for encephalitis.

Table 1. Diagnostic Criteria for Encephalitis and Encephalopathy of Presumed Infectious or Autoimmune Etiology

Major Criterion (required):
Patients presenting to medical attention with altered mental status (defined as decreased or altered level of consciousness, lethargy or personality change) lasting ≥ 24 h with no alternative cause identified.
Minor Criteria (2 required for possible encephalitis; ≥ 3 required for probable or confirmed ^a encephalitis):
Documented fever $\geq 38^\circ\text{C}$ (100.4°F) within the 72 h before or after presentation ^b
Generalized or partial seizures not fully attributable to a preexisting seizure disorder ^c
New onset of focal neurologic findings
CSF WBC count $\geq 5/\text{cubic mm}^d$
Abnormality of brain parenchyma on neuroimaging suggestive of encephalitis that is either new from prior studies or appears acute in onset ^e
Abnormality on electroencephalography that is consistent with encephalitis and not attributable to another cause. ^f

Abbreviations: CNS, central nervous system; CSF, cerebral spinal fluid; EEG, electroencephalogram; RBC, red blood cell; WBC, white blood cell.

^a Confirmed encephalitis requires one of the following: (1) Pathologic confirmation of brain inflammation consistent with encephalitis; (2) Defined pathologic, microbiologic, or serologic evidence of acute infection with a microorganism strongly associated with encephalitis from an appropriate clinical specimen (for examples, see references [1, 2]); or (3) Laboratory evidence of an autoimmune condition strongly associated with encephalitis.

^b Fever is a common finding in patients with acute encephalitis but is nonspecific. The requirement for objective documentation of fever within a restricted time frame of ≤ 72 h after hospitalization was chosen to exclude secondary health-care associated infections. It is recognized that fevers can occur as a result of a number of infections outside of the central nervous system that can cause encephalopathy, as well as with noninfectious entities that mimic encephalitis. It is also recognized that fever may fluctuate and, as such, objective fever may be lacking in patients with infectious encephalitis at the time of clinical assessment. Furthermore, immunosuppressed patients with encephalitis may not mount a fever.

^c Seizures associated with encephalitis may be generalized, suggestive of global CNS dysfunction, or focal, indicating a localized process. Subclinical seizures may also occur and can be a cause of altered sensorium. Seizures associated with high temperatures are relatively common in young children and, if occurring in isolation, do not mandate evaluation for encephalitis. The major requirement for at least 24 h of altered mentation was selected to exclude the post-ictal state seen in patients with febrile seizures.

^d CSF pleocytosis is suggestive of an inflammatory process of the brain parenchyma, meninges, or both (meningoencephalitis). The absence of CSF pleocytosis, however, does not exclude encephalitis. In particular, it is recognized that the CSF may be devoid of cells in immunocompromised patients (Fodor et al., *Neurology* 1998 51:554–59) or early in the course of infection (Weil et al., *Clin Infect Dis* 2002 34:1154–57; Mook-Kanamori et al., *J Am Geriatr Soc* 57:1514–15; Jakob et al., *Crit Care Med* 2012 40:1304–8). Conversely, the CSF profile with inflammation limited to the meninges may be indistinguishable from that in patients with encephalitis. In the majority of cases of encephalitis, however, the absolute number of leukocytes is $< 1000/\text{mm}^3$ and lymphocytes typically predominate. To ensure adequate sensitivity of the definition, the group defined CSF pleocytosis as $\geq 5 \text{ WBC}/\text{mm}^3$. In cases where there are large numbers of red blood cells in the CSF, such as with a traumatic lumbar puncture, the following formula may allow correction of the WBC count: True CSF WBC = actual CSF WBC—(WBC in blood \times RBC in CSF)/RBC in blood (Tunkel A. In Mandel ed., *Principles and Practice of Infectious Diseases*, 7th ed., 2010:1183–88; Bonadio *Pediatr Infect Dis J* 1992 11:423–31). Notably, rules for adjusting leukocytes in blood-contaminated CSF have not been well validated (Bonsu and Harper, *Pediatr Infect Dis J* 2006 25:8–11).

^e Neuroimaging plays a crucial role in the evaluation of patients with suspected encephalitis, as it may support the diagnosis of a specific etiology or identify alternate conditions that mimic encephalitis. Magnetic resonance imaging (MRI) is the radiologic modality of choice for evaluation of patients with suspected encephalitis. Multiple studies have confirmed MRI to be superior to computed tomographic (CT) scanning for demonstration of CNS abnormalities (Tunkel et al. *Clin Infect Dis* 2008 47:303–27; Glaser et al. *Clin Infect Dis* 2006 43:1565–77). MRI may aid in defining an etiology, as localization of inflammation may be suggestive of particular pathogens (eg, temporal lobe involvement in patients with herpes simplex virus encephalitis) or of an autoimmune phenomenon (eg, demyelination in patients with acute disseminated encephalomyelitis). A noncontrast CT scan is most useful in evaluating safety in the performance of a lumbar puncture and in excluding alternative diagnoses such as subarachnoid hemorrhage. We recognize that MRI or CT may not be available in resource-limited settings, in which case the diagnosis of encephalitis will need to rely on clinical and laboratory criteria.

^f EEG abnormalities reported in cases of encephalitis range from nonspecific generalized slowing to distinctive patterns suggestive of specific entities, including repetitive sharp wave complexes over the temporal lobes or periodic lateralizing epileptiform discharges in HSV-1 (Lai and Gragasin *J Clin Neurophysiol* 1988 5:87–103) and bilateral synchronous periodic sharp and slow waves associated with subacute sclerosing panencephalitis (Gutierrez et al. *Dev Med Child Neurol* 2010 52:901–7). EEG abnormalities are frequently nonspecific and may be attributable to medications or metabolic abnormalities. The EEG may identify epileptiform discharges in the absence of clinical evidence of seizure activity (subclinical or nonconvulsive status epilepticus) as a cause of obtundation.

PRIORITY 2: DIAGNOSTIC ALGORITHM

Scope and Purpose

Algorithms for the diagnosis of encephalitis may serve many purposes, including aiding clinicians in management of patients, standardizing evaluations for research, and facilitating public health disease surveillance. Several groups have recently provided reviews of diagnosis and management of encephalitis, with differing purposes and depth [1, 23–26]. Our primary goal was to develop a practical diagnostic algorithm for use by

medical professionals worldwide in the initial evaluation of suspected encephalitis. In addition, we intended the algorithm to provide a standardized approach for use in collaborative, multi-center research studies. Etiologies that we focus on include those that (1) are more commonly identified, (2) may benefit from targeted therapies, or (3) are of particular public health significance. The algorithm is directed toward identification of specific infectious and autoimmune causes of encephalitis and therefore does not include a broad evaluation for mimickers of encephalitis or other causes of encephalopathy.

Table 2. Diagnostic Algorithm for Initial Evaluation of Encephalitis in Adults^a

ROUTINE STUDIES
CSF
Collect at least 20 cc fluid, if possible; freeze at least 5–10 cc fluid, if possible
Opening pressure, WBC count with differential, RBC count, protein, glucose
Gram stain and bacterial culture
HSV-1/2 PCR (if test available, consider HSV CSF IgG and IgM in addition)
VZV PCR (sensitivity may be low; if test available, consider VZV CSF IgG and IgM in addition)
Enterovirus PCR
Cryptococcal antigen and/or India Ink staining
Oligoclonal bands and IgG index
VDRL
SERUM
Routine blood cultures
HIV serology (consider RNA)
Treponemal testing (RPR, specific treponemal test)
Hold acute serum and collect convalescent serum 10–14 d later for paired antibody testing
IMAGING
Neuroimaging (MRI preferred to CT, if available)
Chest imaging (Chest x-ray and/or CT)
NEUROPHYSIOLOGY
EEG
OTHER TISSUES/FLUIDS
When clinical features of extra-CNS involvement are present, we recommend additional testing (eg, biopsy of skin lesions; bronchoalveolar lavage and/or endobronchial biopsy in those with pneumonia/pulmonary lesions; throat swab PCR/culture in those with upper respiratory illness; stool culture in those with diarrhea); also see below
CONDITIONAL STUDIES
HOST FACTORS
Immunocompromised—CMV PCR, HHV6/7 PCR, HIV PCR (CSF); <i>Toxoplasma gondii</i> serology and/or PCR; MTB testing ^b ; fungal testing ^c ; WNV testing ^d
GEOGRAPHIC FACTORS
Africa—malaria (blood smear), trypanosomiasis (blood/CSF smear, serology from serum and CSF); dengue testing ^d
Asia—Japanese encephalitis virus testing ^d ; dengue testing ^d ; malaria (blood smear); Nipah virus testing (serology from serum and CSF; PCR, immunohistochemistry, and virus isolation in a BSL4 lab can also be used to substantiate diagnosis)
Australia—Murray Valley encephalitis virus testing ^d , Kunjin virus testing ^d , Australian Bat Lyssavirus (ABLV) testing ^e
Europe—Tick-borne encephalitis virus (serology); if Southern Europe, consider WNV testing ^d , Toscana virus testing ^d
Central and South America—dengue testing ^d ; malaria (blood smear); WNV, Venezuelan equine encephalitis testing ^d
North America—Geographically appropriate arboviral testing (eg, WNV, Powassan, LaCrosse, Eastern Equine Encephalitis viruses ^d , Lyme (serum ELISA and Western blot)
SEASON AND EXPOSURE
Summer/Fall: Arbovirus ^d and tick-borne disease ^f testing
Cat (particularly if with seizures, paucicellular CSF)—Bartonella antibody (serum), ophthalmologic evaluation
Tick exposure—tick borne disease testing ^f
Animal bite/bat exposure—rabies testing ^e
Swimming or diving in warm freshwater or nasal/sinus irrigation— <i>Naegleria fowleri</i> (CSF wet mount and PCR ^g)
SPECIFIC SIGNS AND SYMPTOMS
Psychotic features or movement disorder—anti-NMDAR antibody (serum, CSF); rabies testing ^e ; screen for malignancy, Creutzfeld-Jakob disease
Prominent limbic symptoms—Autoimmune limbic encephalitis testing ^h ; HHV6/7 PCR (CSF); screen for malignancy
Rapid decompensation (particularly with animal bite history or prior travel to rabies-endemic areas)—rabies testing ^e
Respiratory symptoms— <i>Mycoplasma pneumoniae</i> serology and throat PCR (if either positive, then do CSF PCR); respiratory virus testing ⁱ
Acute flaccid paralysis—Arbovirus testing ^d ; rabies testing ^e
Parkinsonism—Arbovirus testing ^d ; Toxoplasma serology
Nonhealing skin lesions— <i>Balamuthia mandrillaris</i> , <i>Acanthamoeba</i> testing ^g

Table 2 continued.

LABORATORY FEATURES

Elevated transaminases—Rickettsia serology, tick borne diseases testing^f

CSF protein >100 mg/dL, or CSF glucose <2/3 peripheral glucose, or lymphocytic pleocytosis with subacute symptom onset—MTB testing^b, fungal testing^c

CSF protein >100 mg/dL or CSF glucose <2/3 peripheral glucose and neutrophilic predominance with acute symptom onset and recent antibiotic use—CSF PCR for *S. pneumoniae* and *N. meningitidis*

CSF eosinophilia—MTB testing^b; fungal testing^c; *Baylisascaris procyonis* antibody (serum); *Angiostrongylus cantonensis* and *Gnathostoma* sp. testing^l

RBCs in CSF—*Naegleria fowleri* testing^g

Hyponatremia—anti-VGKC antibody (serum); MTB testing^a

NEUROIMAGING FEATURES

Frontal lobe—*Naegleria fowleri* testing (CSF wet mount and PCR^g)

Temporal lobe—VGKC antibodies (serum and CSF); HHV 6/7 PCR (CSF)

Basal ganglia and/or thalamus—Arbovirus^d testing; MTB testing^a

Brainstem—Arbovirus testing^d; Listeria PCR (if available); Brucella antibody (serum); MTB testing^b

Cerebellum—EBV PCR (CSF) and serology

Diffuse cerebral edema—Respiratory virus testingⁱ

Space occupying and/or ring-enhancing lesions—MTB testing^b; fungal testing^c; *Balamuthia mandrillaris* and *Acanthamoeba* testing^g; Toxoplasma serology

Hydrocephalus and/or basilar meningeal enhancement—MTB testing^b; fungal testing^c

Infarction or hemorrhage—MTB testing^b; fungal testing^c; respiratory virus testingⁱ

Abbreviations: ABLV, Australian bat lyssavirus; BSL4, biosafety level 4; CNS, central nervous system; CSF, cerebral spinal fluid; CT, computed tomography; EBV, Epstein-Barr virus; EEG, electroencephalography; ELISA, enzyme-linked immunosorbent assay; HHV, human herpesvirus; HIV, human immunodeficiency virus; HSV, herpes simplex virus; IgG, immunoglobulin G; IgM, immunoglobulin M; MRI, magnetic resonance imaging; MTB, *Mycobacterium tuberculosis*; PCR, polymerase chain reaction; VDRL, Venereal Disease Research Laboratory; VGKC, voltage gated potassium channel; VZV, varicella-zoster virus; RBC, red blood cell; WBC, white blood cell; WNV, West Nile virus.

^a This table is not intended to encompass all causes of encephalitis, nor all epidemiological or laboratory-based risk factors. We recommend using this table as a guideline for initial management of acute encephalitis in adults. For additional information, we recommend consulting Tunkel et al. 2008, Steiner et al. 2010, Solomon et al. 2012 (see references). Consultation with local health authorities is also recommended.

^b MTB testing includes CSF smear for acid-fast bacilli and CSF mycobacterial culture along with one or more of the number of MTB PCR tests for CSF now commercially available. Sensitivity of smear and culture increases with the volume of CSF analyzed; we recommend consulting with the laboratory regarding optimal volumes of CSF to be analyzed. Given the varying sensitivity of these tests, systemic MTB testing including tuberculin skin test (may be negative) or interferon gamma release assay, stains and cultures from sputum, and tissue from biopsies from any potential systemic sites of infection.

^c Fungal testing should be tailored to specific geographic region and prior travel history/place of residence, and typically consists of serology, antibody testing from urine and/or CSF, and cultures from blood and CSF.

^d Arbovirus testing should be tailored to specific geographic region and typically consists of IgG and IgM from serum and CSF; PCR (serum, CSF) can be performed for select arboviruses (ie, WNV, California serogroup viruses), and is particularly useful in immunocompromised patients.

^e Rabies/ABLV testing includes serologic analysis of serum and CSF; virus isolation or RT-PCR from saliva; tests for viral antigen or histopathology on either a brain biopsy or full-thickness biopsy of the nape of the neck. Testing should be conducted in concert with a local or regional public health department.

^f Tick borne disease testing should be tailored to specific geographic region and typically consists of serology (ie, *Borrelia*, *Ehrlichia*, *Rickettsia* sp., *Anaplasma phagocytophilum*, TBEV), and blood PCR (*Ehrlichia*, *Anaplasma*).

^g *Naegleria fowleri*, *Balamuthia mandrillaris*, and *Acanthamoeba* spp. testing is only available at specialized laboratories (eg, CDC) and includes serum immunofluorescence assay, immunohistochemistry on brain or other tissue and PCR testing on brain or other tissue and CSF. In addition, CSF wet mount is recommended for *Naegleria fowleri* testing. Brain tissue from affected region offers optimal sensitivity and specificity but other specimens can be tested.

^h Autoimmune limbic encephalitis evaluation includes testing for antibodies to VGKC (most commonly identified cause in adults), GAD, AMPA receptor, GABA_A receptor, mgluR5, Hu, CV2, Ma2, and amphiphysin.

ⁱ Respiratory virus testing includes either culture or respiratory PCR panel from respiratory specimens (eg, nasopharyngeal swab, nasal wash). Respiratory virus testing should include Influenza A and B (during influenza season). Testing for other respiratory viruses such as parainfluenza and adenovirus should be considered although their role in causing CNS illness is controversial.

^j Limited testing may be available through research laboratories, and includes examination of CSF or other affected tissues (ie, eye, muscle) for presence of parasite, or detection of antibody in serum or CSF.

Description

Relatively few causes account for the vast majority of identified cases of encephalitis [5, 7, 27]. Therefore, we recommend testing for these agents, along with selected, treatable conditions, in all individuals. Obtaining a comprehensive case history, including recent and remote travel, animal contacts

and insect exposure, and carefully characterizing presenting symptoms, signs, and laboratory and neuroimaging findings are crucial to inform additional testing (Tables 2 and 3). We developed distinct algorithms for adult and pediatric populations, because the spectrum and frequencies of etiologies differ between the 2 age groups [27]. We recommend

Table 3. Diagnostic Algorithm for Initial Evaluation of Encephalitis in Children^a

ROUTINE STUDIES
CSF ^b
Collect at least 5 cc fluid, if possible; freeze unused fluid for additional testing
Opening pressure, WBC count with differential, RBC count, protein, glucose
Gram stain and bacterial culture
HSV-1/2 PCR (if test available, consider HSV CSF IgG and IgM in addition)
Enterovirus PCR
SERUM
Routine blood cultures
EBV serology (VCA IgG and IgM and EBNA IgG)
<i>Mycoplasma pneumoniae</i> IgM and IgG
Hold acute serum and collect convalescent serum 10–14 d later for paired antibody testing
IMAGING
Neuroimaging (MRI preferred to CT, if available)
NEUROPHYSIOLOGY
EEG
OTHER TISSUES/FLUIDS
<i>Mycoplasma pneumoniae</i> PCR from throat sample
Enterovirus PCR and/or culture of throat and stool
When clinical features of extra-CNS involvement are present, we recommend additional testing (eg, biopsy of skin lesions; bronchoalveolar lavage and/or endobronchial biopsy in those with pneumonia/pulmonary lesions; throat swab PCR/culture in those with upper respiratory illness; stool culture in those with diarrhea); also see below
CONDITIONAL STUDIES
HOST FACTORS
Age <3 y—Parechovirus PCR (CSF)
Immunocompromised—CMV PCR, HHV6/7 PCR, HIV PCR (CSF); cryptococcal antigen; <i>Toxoplasma gondii</i> serology and/or PCR; MTB testing ^c ; fungal testing ^d ; WNV testing ^e
GEOGRAPHIC FACTORS
Africa—malaria (blood smear); trypanosomiasis (blood/CSF smear, serology from serum and CSF); dengue testing ^e
Asia—Japanese Encephalitis Virus testing ^e ; dengue testing ^e ; malaria (blood smear); Nipah virus testing (serology from serum and CSF; PCR, immunohistochemistry, and virus isolation in a BSL4 lab can also be used to substantiate diagnosis)
Australia—Murray Valley encephalitis virus testing ^e ; Kunjin virus testing ^e , Australian Bat Lyssavirus (ABLV) testing ^f
Europe—Tick-borne Encephalitis Virus (serology); if Southern Europe, consider WNV testing ^e , Toscana virus testing ^e
Central and South America—dengue testing ^e ; malaria (blood smear)
North America—Geographically—appropriate arboviral testing (eg, WNV, Powassan, LaCrosse, Eastern Equine Encephalitis viruses, ^e Lyme (serum ELISA and Western blot)
SEASON AND EXPOSURE
Summer/Fall: Arbovirus ^e and tick-borne disease ^g testing
Cat (particularly if with seizures, paucicellular CSF)—Bartonella antibody (serum), ophthalmologic evaluation
Tick exposure—Tick borne disease testing ^g
Animal bite/bat exposure—rabies testing ^f
Swimming or diving in warm freshwater or nasal/sinus irrigation— <i>Naegleria fowleri</i> (CSF wet mount and PCR ^h)
SPECIFIC SIGNS AND SYMPTOMS
Abnormal behavior (eg, new onset temper tantrums, agitation, aggression), psychotic features, seizures or movement disorder—NMDAR antibody (serum, CSF), oligoclonal bands, IgG index, rabies testing ^f
Behavior changes followed by myoclonic spasms/jerks: measles IgG (CSF and serum)
Vesicular rash—VZV PCR from CSF (sensitivity may be low; if test available, consider CSF IgG and IgM); VZV IgG and IgM from serum
Rapid decompensation (particularly with animal bite history or prior travel to rabies-endemic areas)—rabies testing ^f
Respiratory symptoms—chest imaging (chest X-ray and/or CT scan); respiratory virus testing ⁱ ; <i>Mycoplasma pneumoniae</i> PCR (CSF)
Acute flaccid paralysis—Arbovirus testing ^e ; rabies testing ^f
Parkinsonism—Arbovirus testing ^e ; <i>Toxoplasma</i> serology
Nonhealing skin lesions— <i>Balamuthia</i> , <i>Acanthamoeba</i> testing ^h
Prominent limbic symptoms—Autoimmune limbic encephalitis testing ^j , HHV6/7 PCR (CSF)

Table 3 continued.

LABORATORY FEATURES

If EBV serology is suggestive of acute infection, perform EBV PCR (CSF)

Elevated transaminases—Rickettsia serology, tick borne diseases testing^g

CSF protein >100 mg/dL, or CSF glucose <2/3 peripheral glucose, or lymphocytic pleocytosis with subacute symptom onset—MTB testing^c, fungal testing^d, *Balamuthia mandrillaris* testing^h

CSF protein >100 mg/dL or CSF glucose <2/3 peripheral glucose and neutrophilic predominance with acute symptom onset and recent antibiotic use—CSF PCR for *S. pneumoniae* and *N. meningitidis*

CSF eosinophilia—MTB testing^c; fungal testing^d; *Baylisascaris procyonis* antibody (serum and CSF); *Angiostrongylus cantonensis*, *Gnathostoma* sp. testing^k

Hyponatremia—MTB testing^c

Mycoplasma pneumoniae serology or throat PCR positive—*Mycoplasma pneumoniae* PCR (CSF)

NEUROIMAGING FEATURES

Frontal lobe—*Naegleria fowleri* (CSF wet mount and PCR^h)

Temporal lobe—HHV 6/7 PCR (CSF)

Basal ganglia and/or thalamus—Respiratory virus testingⁱ; Arbovirus testing^e; MTB testing^c

Brainstem—respiratory virus testingⁱ; Arbovirus testing^e; Listeria PCR (if available); Brucella antibody (serum); MTB testing^c

Cerebellum—VZV PCR from CSF (sensitivity may be low; if test available, consider CSF IgG and IgM); VZV IgG and IgM from serum; EBV PCR (CSF)

Diffuse cerebral edema—respiratory virus testingⁱ

Space occupying and/or ring-enhancing lesions—MTB testing^c; fungal testing^d; *Balamuthia mandrillaris* and *Acanthamoeba* testing^h, *Toxoplasma gondii* serology

Hydrocephalus and/or basilar meningeal enhancement—MTB testing^c; fungal testing^d; *Balamuthia mandrillaris* testing^h; Infarction or hemorrhage—MTB testing^c; fungal testing^d; respiratory virus testingⁱ;

White matter lesions—Oligoclonal bands, IgG index, Lyme (serum ELISA and Western blot); Brucella (serology or CSF culture);

Measles virus testing for SSPE; *Baylisascaris procyonis* antibody (serum and CSF); *Balamuthia mandrillaris* testing^h

Abbreviations: ABLV, Australian bat lyssavirus; BSL4, biosafety level 4; CNS, central nervous system; CMV, cytomegalovirus; CSF, cerebral spinal fluid; CT, computed tomography; EBV, Epstein-Barr virus; EBNA, Epstein-Barr virus nuclear antigen; EEG, electroencephalography; ELISA, enzyme-linked immunosorbent assay; HHV, human herpesvirus; HIV, human immunodeficiency virus; HSV, herpes simplex virus; IgG, immunoglobulin G; IgM, immunoglobulin M; MRI, magnetic resonance imaging; MTB, *Mycobacterium tuberculosis*; PCR, polymerase chain reaction; RBC, red blood cell; HSV, herpes simplex virus; RBC, red blood cell; NMDAR, N-methyl-D-aspartate receptor; VCA, viral capsid antigen; VDRL, Venereal Disease Research Laboratory; VGKC, voltage gated potassium channel; VZV, varicella-zoster virus; SSPE, subacute sclerosing panencephalitis; WBC, white blood cell; WNV, West Nile virus.

^a This table is not intended to encompass all causes of encephalitis, nor all epidemiological or laboratory-based risk factors. We recommend utilizing this table as a guideline for initial management of acute encephalitis in children beyond the neonatal period. For additional information, we recommend consulting Tunkel et al. 2008, Steiner et al. 2010, Kneen et al. 2012 (see references). Consultation with local health authorities is also recommended.

^b Although some members of the consortium recommended *M. pneumoniae* CSF PCR as routine testing for all children, a consensus was not reached given the challenges of establishing a diagnosis of encephalitis due to *M. pneumoniae* (see text).

^c MTB testing includes CSF smear for acid-fast bacilli and CSF mycobacterial culture along with one or more of the number of MTB PCR tests for CSF now commercially available. Sensitivity of smear and culture increases with the volume of CSF analyzed; we recommend consulting with the laboratory regarding optimal volumes of CSF to be analyzed. Given the varying sensitivity of these tests, systemic MTB testing including tuberculin skin test (may be negative) or interferon gamma release assay, stains and cultures from sputum, and tissue from biopsies from any potential systemic sites of infection.

^d Fungal testing should be tailored to specific geographic region and prior travel history/place of residence, and typically consists of serology, antibody testing from urine and/or CSF, and cultures from blood and CSF.

^e Arbovirus testing should be tailored to specific geographic region and typically consists of IgG and IgM from serum and CSF; PCR (serum, CSF) can be performed for select arboviruses (ie, WNV, California serogroup viruses), and is particularly useful in immunocompromised patients.

^f Rabies/ABLV testing includes serologic analysis of serum and CSF; virus isolation or RT-PCR from saliva; tests for viral antigen or histopathology on either a brain biopsy or full-thickness biopsy of the nape of the neck. Testing should be conducted in concert with a local or regional public health department.

^g Tick borne disease testing should be tailored to specific geographic region and typically consists of serology (ie, *Borrelia*, *Ehrlichia*, *Rickettsia* sp., *Anaplasma phagocytophilum*, TBEV), and blood PCR (*Ehrlichia*, *Anaplasma*).

^h *Naegleria fowleri*, *Balamuthia mandrillaris*, and *Acanthamoeba* spp. testing is only available at specialized laboratories (eg, CDC) and includes serum immunofluorescence assay, immunohistochemistry on brain or other tissue and PCR testing on brain or other tissue and CSF. In addition, CSF wet mount is recommended for *Naegleria fowleri* testing. Brain tissue from affected region offers optimal sensitivity and specificity but other specimens can be tested.

ⁱ Respiratory virus testing includes either culture or respiratory PCR panel from respiratory specimens (eg, nasopharyngeal swab, nasal wash). Respiratory virus testing should include Influenza A and B (during influenza season). Testing for other respiratory viruses including Parainfluenza 1–4, Adenovirus, and human metapneumovirus should be considered although their role in causing CNS illness is controversial.

^j Autoimmune limbic encephalitis evaluation includes testing for antibodies to VGKC, GAD, AMPA receptor, GABA_b receptor, mgluR5, Hu, CV2, Ma2, and amphiphysin.

^k Limited testing may be available through research laboratories, and includes examination of CSF or other affected tissues (ie, eye, muscle) for presence of parasite, or detection of antibody in serum or CSF.

neuroimaging (preferably magnetic resonance imaging [MRI]), electroencephalography (EEG), and lumbar puncture (LP) in all individuals unless contraindicated [28], because such testing may confirm the diagnosis of encephalitis and establish the etiology.

If the etiology of encephalitis is not rapidly identified or where unique epidemiologic factors or clinical features are present, we recommend referring to several recent publications as a guide to further evaluation [1, 23–26]. Our recommendations incorporate large-scale geographic considerations; however, specific travel history or geographic information should prompt consultation with regional public health departments. Because our focus is on initial evaluation of patients, modalities such as brain biopsy, typically reserved for refractory cases of encephalitis, are not included. Moreover, our knowledge of autoimmune encephalitis is rapidly changing, with ongoing identification of novel autoantibodies and expansion of clinical spectra of disease. Here, we include well-recognized syndromes and relatively common etiologies [29, 30]. Overall, it should be noted that our recommendations provide general guidance for initial evaluation of encephalitis, but rapid advances in autoimmune encephalitis coupled with the emerging nature of infections warrant ongoing evaluation of testing paradigms.

Selected Etiology-specific Considerations

Herpes Simplex Virus (HSV)

Case series and studies have shown that HSV polymerase chain reaction (PCR) can be falsely negative, especially among children and early in the disease course [18, 21, 31]. If testing from the first LP is negative and herpes simplex encephalitis (HSE) is still of concern (eg, temporal lobe involvement seen on neuroimaging), a second LP should be repeated within 3–7 days with CSF sent for HSV PCR [1]. Testing for intrathecal HSV antibodies may complement molecular testing but is not typically useful for acute patient management [32].

Varicella-zoster Virus (VZV)

VZV is one of the most commonly identified causes of acute encephalitis in adults [5, 7], typically associated with viral reactivation and resulting in a CNS vasculopathy [33]. Notably, CNS reactivation may occur in the absence of skin lesions [34]. In children, on the other hand, most cases occur concurrently with chickenpox or in a post-infectious form [22, 35]. Detection of antibodies to VZV in the CSF appears to have greater sensitivity than detection of viral DNA [36]; therefore, we recommend that both assays be sent when possible.

Enteroviruses (EV)

CSF PCR analysis is crucial to perform but alone may be insufficient for diagnosis. In one report of an EV71 outbreak, EV-PCR of CSF yielded positive results in only 31% of cases, with higher yields from PCR of throat and stool specimens [37]. Because

enteroviral shedding from the gastrointestinal tract may persist for weeks following infection [38], we recommend testing of both CNS and extra-CNS samples. Moreover, because standard EV PCR assays do not detect parechoviruses, specific PCR assays for these viruses should be performed in young children.

Epstein-Barr Virus (EBV)

EBV is an important cause of encephalitis in the pediatric population, particularly among adolescents. Although helpful in diagnosis of EBV-associated encephalitis, PCR testing can be associated with false-negative and false-positive results, the latter often occurring due to presence of EBV DNA in peripheral blood mononuclear cells. Therefore, serology, including antiviral capsid antigens (VCA) immunoglobulin M/immunoglobulin G (IgM/IgG) and anti-Epstein-Barr nuclear antigen (EBNA), is recommended in addition to CSF PCR [39].

Human Herpesvirus 6 (HHV-6)

The CNS pathogenic potential of HHV-6 has yet to be defined, although increasing evidence implicates its role in limbic encephalitis in the immunocompromised individual [40]. A positive HHV-6 CSF PCR should prompt corresponding evaluation of blood PCR levels in an effort to distinguish between chromosomal integration and acute infection [41]. Notably, latent disease can also be detected through PCR and may be a confounder [42].

Arboviruses

For most arboviruses, serologic testing of serum and CSF is preferred to molecular testing, since the peak of viremia typically occurs prior to symptom onset. For example, in patients with West Nile virus (WNV) associated with neuroinvasive disease, CSF PCR is relatively insensitive (57%) compared with detection of WNV IgM in CSF [43]. The cumulative percentage of seropositive patients increases by approximately 10% per day during the first week of illness, suggesting the need for repeat testing if the suspicion for disease is strong in those with initially negative results [44, 45]. Notably, arbovirus IgM antibodies may be persistently detectable in the serum and, less commonly, in the CSF, for many months after acute infection, and therefore may not be indicative of a current infection [46, 47]. Therefore, if possible, documentation of acute infection by seroconversion and/or 4-fold or greater rises in titre using paired sera is recommended.

Mycoplasma pneumoniae

Several reports have implicated *Mycoplasma pneumoniae* as a leading cause of encephalitis, particularly among children [48, 49]. In most such cases an immune-mediated mechanism is hypothesized; a preceding respiratory prodrome and detection of the pathogen in the respiratory tract, but not CSF, is typical of such cases. Direct infection of the brain or CSF is less common but has been observed in both adults and children. Serology alone

is unreliable in diagnosing neurologic disease due to *M. pneumoniae* because of the high background incidence of acute infections and limited specificity of currently available assays [50]. Similarly, because detection of *M. pneumoniae* DNA in respiratory secretions may reflect acute infection, remote infection or asymptomatic colonization its detection does not establish it as the cause of neurologic disease. We recommend that testing be performed in pediatric patients and include both serology and PCR analysis. Overall, the strength of microbiologic evidence needs to be considered when implicating *M. pneumoniae* as the cause of encephalitis [51].

Anti-NMDA Receptor (NMDAR) Encephalitis

Affected individuals typically develop prominent psychiatric symptoms, cognitive dysfunction, seizures, orofacial dyskinesias, and autonomic instability [52, 53]. Sensitivity of testing is approximately 15% higher from the CSF than from serum, as determined by comparison of paired serum and CSF samples [54]. Notably, the recent demonstration of serum or CSF antibodies to NMDAR in 30% of individuals during the course of typical HSE suggests that a positive antibody result should be interpreted in the proper clinical context [55].

Autoimmune Limbic Encephalitis (ALE)

ALE, characterized by rapidly progressive short-term memory deficits, psychiatric symptoms, and seizures, is associated with a wide variety of autoantibodies, including onconeural antibodies (ie, Hu, CV2, Ma2, amphiphysin) and antibodies to neuronal cell surface/ synaptic antigens (ie, voltage gated potassium channel [VGKC], glutamic acid decarboxylase, AMPA receptor, GABA_b receptor, mgluR5). Although the former group is highly associated with underlying tumor, in the latter group the presence of malignancy is variable. In most cases, serum testing is sufficient [56].

Summary

This algorithm represents a practical tool for use by clinicians in initial evaluation of patients with suspected encephalitis and provides the basis for worldwide collaboration to advance diagnosis and management of affected individuals. To maximize the benefits of such an approach for research purposes, the use of standardized case history forms with relevant demographic and laboratory data is critical.

PRIORITY 3: HOST GENETICS

Introduction

Although encephalitis is typically a rare clinical entity, it follows infection with a number of relatively common agents. Reasons for this range of disease severity remain unclear. Several general and disease-specific risk modifiers have been

identified, including infectious dose, viral or microbial genotypic variation, and age-related changes in anatomic barriers or global immune function. In addition, an individual's genetic make-up contributes significantly to the variation in infectious disease susceptibility and severity [57]. Preclinical studies have identified host cell factors that modulate the course of infection for a range of microbes. With few exceptions, however, these studies have failed to identify genes in which human variation affects disease outcome. Indeed, risk alleles for infectious encephalitis have only been identified in a handful of cases (Table 4 and references).

Challenges and Solutions

The rarity and highly sporadic nature of encephalitis presents certain challenges. The strategy and approach to identifying genotypic determinants of a given phenotype depends largely on its allelic architecture—the number, type, penetrance, and frequency of disease associated variants (Supplementary Table 2) [58]. Mendelian traits, representing one extreme on the allelic spectrum, are determined by variants at a single locus. Because Mendelian variants are associated with a high relative risk of disease, they tend to be very rare in populations. Such traits have typically been dissected through linkage studies of families. While this approach has successfully identified genes involved in primary immunodeficiency, it is difficult to identify large pedigrees with multiple exposed and affected individuals for encephalitis and many other infectious diseases [57]. Genomewide resequencing of unrelated cases has emerged as another promising approach in Mendelian disease genetics. This strategy can identify candidate genes with as few as 10–50 individuals, but the case only design necessitates larger validation studies with appropriate controls [59, 60].

On the other end of the allelic spectrum are common genetic variants, which typically have only a modest effect on a disease phenotype. The common disease-common variant hypothesis predicts that many prevalent diseases are the result of common variants in multiple genetic loci, each with a small relative risk. These loci are typically identified in case-control association studies, although even the best candidate gene studies are prone to confounding and bias. While genomewide association studies circumvent many of these issues, adequate statistical power requires recruitment of hundreds or thousands of affected cases and exposed controls [61]. Even then, current study designs are poorly sensitive for rare alleles.

Given the large number of cases required and the cost of genomewide studies, human genetics has become a highly collaborative enterprise. However, many challenges exist in organizing such a genetics research effort. Above all, a multicenter approach will require a set of standard protocols for prospective subject recruitment, informed consent, biospecimen collection, and storage. While many investigators routinely collect serum

Table 4. Risk Alleles Identified for Infectious Encephalitis

Agent	Genes	Study Design	Findings
West Nile Virus	OASL	Candidate gene case control	Synonymous single nucleotide polymorphism (SNP) associated with symptomatic infection ^a ; Result not replicated in several studies ^{b,c} .
	OAS1	Candidate gene case control in 5 different cohorts	Intronic SNP associated with seropositivity (acquisition) ^d . A separate study could not replicate the finding, but did identify a second SNP associated with severe disease ^e
	CCR5	Candidate gene case control in 5 different cohorts	CCD5del32 associated with symptomatic infection and fatal outcome in one cohort ^{d,e} . Not associated with seropositivity (acquisition) ^f ; Result was not replicated by Bigham et al ^c .
	IRF3	Candidate gene case control	Autosomal dominant SNP associated with symptomatic cases compared to asymptomatic, seropositive controls. Association not observed with random blood donor controls ^c .
	MX1	Candidate gene case control	Autosomal recessive SNP associated with symptomatic cases compared to asymptomatic, seropositive controls. Association not observed with random blood donor controls ^c .
Herpes simplex virus	UNC93B	Functional studies and candidate gene sequencing	Autosomal recessive deficiency of functional gene product in two patients leading to impaired interferon-mediated antiviral response ^g .
	TLR3	Functional studies and candidate gene sequencing	Autosomal recessive deficiency in one patient and autosomal dominant variant identified in two patients. Both lead to impaired interferon-mediated antiviral response ^{h,i} .
	TRAF3	Functional studies and candidate gene sequencing	Autosomal dominant variant that functions as a dominant negative, resulting in impaired tumor necrosis factor (TNF) receptor signaling and interferon induction ⁱ .
	TRIF	Functional studies and candidate gene sequencing	Autosomal dominant and autosomal recessive defects, each in a single patient, resulting in impaired toll-like receptor signaling and antiviral responses ^k .
	STAT1	Functional studies and candidate gene sequencing	Two different autosomal recessive alleles, each identified in a single patient, leading to impaired interferon-mediated signaling and antiviral responses ^l .
	TBK1	Functional studies and candidate gene sequencing	Two different autosomal dominant variants, each identified in a single patient, resulting in impaired toll-like receptor signaling ^m .
Tickborne encephalitis virus	CCR5	Candidate gene case control	CCD5del32 associated with tickborne encephalitis ⁿ .

^a Yakub et al., J Infect Dis 2005; 192:1741–48.

^b Lim et al., PLoS Pathog 2009; 5:e1000321.

^c Bigham et al., PLoS ONE 2011; 6:e24745.

^d Glass et al. J Exp Med 2006; 203:35–40.

^e Lim et al. J Infect Dis 2008; 197:262–65.

^f Lim et al., J Infect Dis 2010; 201:178–85.

^g Casrouge et al. Science 2006; 314:308–12.

^h Guo et al. J Exp Med 2011; 208:2083–98.

ⁱ Zhang et al. Science 2007; 317:1522–27.

^j Perez de Diego et al., Immunity 2010; 33:400–411.

^k Sancho-Shimizu et al., J Clin Invest 2011; 121:4889–902.

^l Dupuis et al., Nat Genet 2003; 33:388–91.

^m Herman et al., J Exp Med 2012; 209:2567–1582.

ⁿ Kindberg et al. J Infect Dis 2008; 197:266–69.

and CSF from enrolled patients, protocols would need to be expanded to include snap-frozen whole blood with explicit authorization for future use in genetic studies. Similarly, common case history forms are needed to record demographics and relevant risk factors. Ideally, the biospecimens and clinical metadata would be curated and maintained in a central biobank with a mature informational technology infrastructure. The cost of such efforts would be significant.

The group also discussed how research efforts could impact the diagnosis and management of encephalitis. The rapid pace of gene discovery suggests a future in which genetic testing targets high-risk patients in need of immunization or those who would benefit from specific therapeutic interventions. This approach is now commonplace in oncology. In infectious disease, testing for HLA-B5701 is used to identify patients infected with human immunodeficiency virus (HIV) at risk for abacavir hypersensitivity [62], and IL-28B genotype may predict the clinical efficacy of interferon regimens for hepatitis C [63].

Summary

Overall, the identification of genetic risk factors for encephalitis and other neuroinvasive complications of infection is a priority research area. We expect that a more complete understanding of encephalitis host genetics will elucidate pathogenic mechanisms, define relevant biomarkers, and suggest potential therapeutic approaches. As is the case for clinical risk factors, genetic risk factors for encephalitis will likely include alleles that are pathogen-specific as well as mutations that confer broad susceptibility to encephalitis [64]. More work is clearly needed in this area, and this and other consortia can play a productive role in this movement to personalized medicine.

PRIORITY 4: SELECTED EMERGING AREAS

A discussion of selected emerging areas in encephalitis was held together with colleagues from the Centers for Disease Control and Prevention and Public Health Agency of Canada who attended our consortium meeting. Here, we identify priorities for the study of three pathogen groups: arboviruses, lyssaviruses (including rabies), and free living amoebae (FLA) (Table 5).

Arboviruses

Most arboviruses of medical importance belong to 3 families: *Flaviviridae*, *Togaviridae*, and *Bunyaviridae* [65, 66]. Japanese encephalitis virus (JEV) is the leading cause of mosquito-borne encephalitis globally and continues to expand its range, Tick-borne encephalitis virus (TBEV) is the most common arthropod transmitted viral infection of humans in Europe, and increasing numbers of cases of neuroinvasive disease have been documented in North America involving tick-transmitted Powassan virus [66–69]. West Nile virus (WNV) has re-emerged

as an important cause of encephalitis in the United States and Europe, and there has been increasing recognition of dengue (the most common arboviral infection worldwide) and chikungunya viruses as causes of neurological complications [70–74]. La Crosse virus continues to be a leading cause of pediatric encephalitis in the United States, whereas detection of other members of the California serogroup causing severe disease may be hampered by a lack of commercially available diagnostic assays and low level surveillance [75, 76] (Table 5).

Lyssaviruses

Rabies, an acute progressive viral encephalitis with the highest case fatality known for any agent, is caused by viruses in the family *Rhabdoviridae*, genus *Lyssavirus*. Although rabies is one of the oldest infectious diseases, and efficacious human and animal vaccines were developed decades ago, the global public health and veterinary burden remains high. Tens of thousands of human deaths, and millions of exposures, occur annually, mostly in developing countries [77]. Reservoirs predominate among the Carnivora and Chiroptera (bats) [78, 79]. Outcome after exposure likely represents a continuum, defined in part by viral type, dose, route, and poorly understood host attributes [80, 81]. The reduction of exposure to rabid animals and postexposure prophylaxis after an animal bite are the 2 most relevant strategies to prevent additional human cases [82–84]. Elimination of canine rabies by mass vaccination, humane population management, and production of more effective, less costly biologics are solutions to reduce the burden [85, 86] (Table 5).

Free Living Amoebae (FLA)

Several FLA, including *Naegleria fowleri*, *Balamuthia mandrillaris*, and *Acanthamoeba* spp. cause CNS infections. *N. fowleri* causes primary amoebic meningoencephalitis (PAM), whereas *B. mandrillaris* and *Acanthamoeba* spp. generally cause a more chronic disease, granulomatous amoebic encephalitis (GAE). Although case reports of PAM are rare, many additional cases likely go unrecognized, as suggested by the 75% of US PAM cases that are diagnosed postmortem (CDC unpublished data). Prior to 2010, PAM cases were reported only from southern US states. Recently, however, 4 cases were reported from Northern and Midwestern states (CDC unpublished data). Exposure to FLA is believed to be common; a recent serologic investigation showed 3%–4% of individuals with evidence of *B. mandrillaris* exposure [87]. It remains unclear why some develop disease while the majority of those exposed do not [88]. *B. mandrillaris* GAE, previously only reported as isolated cases, has recently been diagnosed in multiple organ transplant recipients where the donor was found to have had *B. mandrillaris* infection, highlighting this organism as a potentially under-recognized cause of fatal encephalitis [89, 90]. Our knowledge of the contribution of FLA to human disease is limited by the lack of

Table 5. Emerging Issues in Encephalitis (Selected Agents)

Agent	Challenge	Recent Progress	Recommendations/Future Directions
Arboviruses	Epidemiology: Re-emergence/resurgence (WNV); Expansion of geographic range (JEV, LACV);	Use of spatial and temporal statistics to impute etiologies ^a	Enhanced surveillance, data mining, and utilization of a wider panel of arbovirus diagnostic assays
	Epidemiology: Under-recognition of arboviruses as agents of neurologic disease	Increased awareness among physicians to include a variety of arboviruses in differential diagnosis	Ongoing research to better understand arbovirus pathogenesis, ecology, and the factors contributing to emergence, activity, and outbreaks
	Prevention: Vaccines unavailable for many arboviruses	Some success with vaccination against JEV and TBEV	Improved public health messaging regarding personal preventative measures to decrease risk for exposure; increased use of JEV vaccine for prevention in children in risk areas
		Four WNV vaccines currently in human trials ^b	Further development of a vaccine for WNV targeted at vulnerable populations
		Tetravalent dengue vaccine showed modest efficacy; large scale studies are in progress ^c	Further development and validation of dengue vaccine to induce long-term protective immunity against all 4 dengue serotypes simultaneously
	Treatment: Lack of specific therapeutics	Advances in the study of pathogenesis and informed drug design, with several candidate therapeutic platforms being evaluated ^{d,e}	More effective bridging of in vitro and animal studies with translational research/clinical trials
Rabies (Lyssavirus)	Epidemiology: Need for enhanced surveillance	Recognition of "milder" forms of disease and broader understanding as a continuum	Wider inclusion in the differential diagnosis of encephalitis even without a history of animal exposure
	Prevention: Optimization of prevention programs	Experimentation with abbreviated and lower-dose vaccination schedules to lower cost and improve accessibility ^f	Improved animal control and more widespread vaccination programs towards human rabies prevention and canine rabies elimination
	Treatment: Lack of specific therapeutics	"Milwaukee protocol" reported to show some promise, though subsequent reports inconclusive ^g	Evaluation of inhibitors of RNA replication, neuroprotectants and better understanding of pathogenesis
Free living amoebae	Epidemiology: Relatively few cases and low level surveillance impedes our understanding of disease	Recognition of nasal irrigation for medical or religious purposes as a risk factor for PAM ^h	Serosurveys to define prevalence of disease; more widespread environmental testing to delineate reservoirs of disease
	Diagnosis: Limited recognition and availability of diagnostic testing	Consistent case definitions agreed upon by CDC and Council of State and Territorial Epidemiologists (CSTE)	More rapid diagnostics are critical given short therapeutic window
	Treatment: Lack of widely available and robust treatments	Miltefosine treatment for GAE ⁱ ; Corifungin for FLA in vitro ^j	Further evaluation of miltefosine, corifungin, and other agents in humans

Abbreviations: CDC, Centers for Disease Control and Prevention; FLA, free living amoebae; GAE, granulomatous amoebic encephalitis; JEV, Japanese encephalitis virus; LACV, La Crosse Virus; PAM, primary amoebic meningoencephalitis; TBEV, Tick-borne encephalitis virus; WNV, West Nile virus.

^a Kulkarni et al., *Epidemiology and Infection* 2012 (epub ahead of print).

^b De Filette et al., *Vet Res* 2012; 43:16.

^c Sabchareon et al. *Lancet* 2012; 380:1559–67.

^d Lee et al., *J Gen Virol* 2012; 93:20–26.

^e Suthar et al., *Nat Rev Microbiol* 2013; 11:115–28.

^f Wieten et al., *Clin Infect Dis* 2013; 414–19.

^g Jackson AC, *Antiviral Res* 2013 (epub ahead of print).

^h Yoder et al. *Clin Infect Dis* 2012; 55:e79–85.

ⁱ Kim et al., *Antimicrob Agents Chemother* 2008; 52:4010–16.

^j Debnath et al. *Antimicrob Agents Chemother* 2012; 56:5450–57.

consistent surveillance data and a restricted understanding of the ecology of FLA (Table 5).

Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online (<http://cid.oxfordjournals.org/>). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. We thank members of the International Encephalitis Consortium whose discussions informed this article: Heather Sheriff, David Brown, Eileen Farnon, Sharon Messenger, Beverley Paterson, Ariane Soldatos, Sharon Roy, Govinda Visvesvara, Michael Beach, Roger Nasci, Carol Pertowski, Scott Schmid, Lisa Rascoe, Joel Montgomery, Suxiang Tong, Robert Breiman, Richard Franka, Matt Keuhnert, Fred Angulo, and James Cherry. We are grateful to the Seiler family and friends for their generosity, which helped to support the first International Encephalitis Consortium meeting.

Disclaimer. The findings and conclusions in this report are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention, or any other United States Government agency.

Financial support. This work was supported by the Emerging Infectious Diseases Program of the Centers for Disease Control and Prevention U50/CCU915548–03 to C. A. G. and U50/CCU416123 to K. C. B.; French Institute for Public Health Surveillance and French Infectious Diseases Society (A. M. and J.-P. S.); National Natural Science Foundation of China [8129034] (L. G.-D.); Hunter Medical Research Institute (K. E. and D. D.); National Institutes of Health K08 AI081754 (A. S. L.); Manitoba Health Research Council (M. V. S.); Public Health England (J. G.).

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: Clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* **2008**; 47:303–27.
2. Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. *Lancet Infect Dis* **2010**; 10:835–44.
3. Kolski H, Ford-Jones EL, Richardson S, et al. Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994–1995. *Clin Infect Dis* **1998**; 26:398–409.
4. Ball R, Halsey N, Braun MM, et al. Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the vaccine: Adverse Event Reporting System. *J Clin Epidemiol* **2002**; 55:819–24.
5. Glaser CA, Honarmand S, Anderson LJ, et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. *Clin Infect Dis* **2006**; 43:1565–77.
6. Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine* **2007**; 25:5771–92.
7. Mailles A, Stahl JP. Infectious encephalitis in France in 2007: a national prospective study. *Clin Infect Dis* **2009**; 49:1838–47.
8. Noah DL, Bresee JS, Gorensek MJ, et al. Cluster of five children with acute encephalopathy associated with cat-scratch disease in south Florida. *Pediatr Infect Dis J* **1995**; 14:866–9.
9. Armengol CE, Hendley JO. Cat-scratch disease encephalopathy: a cause of status epilepticus in school-aged children. *J Pediatr* **1999**; 134:635–8.
10. Easley RB, Cooperstock MS, Tobias JD. Cat-scratch disease causing status epilepticus in children. *South Med J* **1999**; 92:73–6.
11. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. *Clin Infect Dis* **2002**; 35:512–7.
12. Newland JG, Romero JR, Varman M, et al. Encephalitis associated with influenza B virus infection in 2 children and a review of the literature. *Clin Infect Dis* **2003**; 36:e87–95.
13. Weitkamp JH, Spring MD, Brogan T, Moses H, Bloch KC, Wright PF. Influenza A virus-associated acute necrotizing encephalopathy in the United States. *Pediatr Infect Dis J* **2004**; 23:259–63.
14. van Zeijl JH, Bakkers J, Wilbrink B, Melchers WJ, Mullaart RA, Galama JM. Influenza-associated encephalopathy: no evidence for neuroinvasion by influenza virus nor for reactivation of human herpesvirus 6 or 7. *Clin Infect Dis* **2005**; 40:483–5.
15. Bloch KC, Glaser C. Diagnostic approaches for patients with suspected encephalitis. *Curr Infect Dis Rep* **2007**; 9:315–22.
16. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. *Lancet Neurol* **2011**; 10:63–74.
17. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. *Clin Infect Dis* **2012**; 54:899–904.
18. Weil AA, Glaser CA, Amad Z, Forghani B. Patients with suspected herpes simplex encephalitis: rethinking an initial negative polymerase chain reaction result. *Clin Infect Dis* **2002**; 34:1154–7.
19. Mook-Kanamori B, van de Beek D, Wijdicks EF. Herpes simplex encephalitis with normal initial cerebrospinal fluid examination. *J Am Geriatr Soc* **2009**; 57:1514–5.
20. Jakob NJ, Lenhard T, Schnitzler P, et al. Herpes simplex virus encephalitis despite normal cell count in the cerebrospinal fluid. *Crit Care Med* **2012**; 40:1304–8.
21. Elbers JM, Bitnun A, Richardson SE, et al. A 12-year prospective study of childhood herpes simplex encephalitis: is there a broader spectrum of disease? *Pediatrics* **2007**; 119:e399–407.
22. Puchhammer-Stöckl E, Popow-Kraupp T, Heinz FX, Mandl CW, Kunz C. Detection of varicella-zoster virus DNA by polymerase chain reaction in the cerebrospinal fluid of patients suffering from neurological complications associated with chicken pox or herpes zoster. *J Clin Microbiol* **1991**; 29:1513–6.
23. Steiner I, Budka H, Chaudhuri A, et al. Viral encephalitis: a review of diagnostic methods and guidelines for management. *Eur J Neurol* **2005**; 12:331–43.
24. Steiner I, Budka H, Chaudhuri A, et al. Viral meningoencephalitis: a review of diagnostic methods and guidelines for management. *Eur J Neurol* **2010**; 17:999–1009.
25. Kneen R, Michael BD, Menson E, et al. Management of suspected viral encephalitis in children—Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group national guidelines. *J Infect* **2012**; 64:449–77.
26. Solomon T, Michael BD, Smith PE, et al. Management of suspected viral encephalitis in adults—Association of British Neurologists and British Infection Association National Guidelines. *J Infect* **2012**; 64:347–73.
27. de Ory F, Avellón A, Echevarría JE, et al. Viral infections of the central nervous system in Spain: A prospective study. *J Med Virol* **2013**; 85:554–62.
28. Roos KL. Lumbar puncture. *Semin Neurol* **2003**; 23:105–14.
29. Rosenfeld MR, Dalmau JO. Paraneoplastic disorders of the CNS and autoimmune synaptic encephalitis. *Continuum (Minneapolis)* **2012**; 18:366–83.

30. Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. *J Neurol Neurosurg Psychiatry* **2012**; *83*: 638–45.
31. De Tiège X, Héron B, Lebon P, Ponsot G, Rozenberg F. Limits of early diagnosis of herpes simplex encephalitis in children: a retrospective study of 38 cases. *Clin Infect Dis* **2003**; *36*:1335–9.
32. Klapper PE, Cleator GM. European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis. *Clin Microbiol Infect* **1998**; *4*:178–80.
33. Amlie-Lefond C, Kleinschmidt-DeMasters BK, Mahalingam R, Davis LEGilden DH. The vasculopathy of varicella-zoster virus encephalitis. *Ann Neurol* **1995**; *37*:784–90.
34. Gregoire SM, van Pesch V, Goffette S, Peeters A, Sindic CJ. Polymerase chain reaction analysis and oligoclonal antibody in the cerebrospinal fluid from 34 patients with varicella-zoster virus infection of the nervous system. *J Neurol Neurosurg Psychiatry* **2006**; *77*: 938–42.
35. De Broucker T, Mailles A, Chabrier S, Morand P, Stahl JP, group scai. Acute varicella zoster encephalitis without evidence of primary vasculopathy in a case-series of 20 patients. *Clin Microbiol Infect* **2012**; *18*: 808–19.
36. Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. *Lancet Neurol* **2009**; *8*:731–40.
37. Pérez-Vélez CM, Anderson MS, Robinson CC, et al. Outbreak of neurologic enterovirus type 71 disease: A diagnostic challenge. *Clin Infect Dis* **2007**; *45*:950–7.
38. Han J, Ma XJ, Wan JF, et al. Long persistence of EV71 specific nucleotides in respiratory and feces samples of the patients with Hand-Foot-Mouth Disease after recovery. *BMC Infect Dis* **2010**; *10*:178.
39. Doja A, Bitnun A, Jones EL, et al. Pediatric Epstein-Barr Virus-Associated Encephalitis: 10-Year Review. *J Child Neurol* **2006**; *21*: 385–91.
40. Tyler KL. Emerging viral infections of the central nervous system: part 1. *Arch Neurol* **2009**; *66*:939–48.
41. Ward KN, Leong HN, Thiruchelvam AD, Atkinson CE, Clark DA. Human herpesvirus 6 DNA levels in cerebrospinal fluid due to primary infection differ from those due to chromosomal viral integration and have implications for diagnosis of encephalitis. *J Clin Microbiol* **2007**; *45*:1298–304.
42. Agut H. Deciphering the clinical impact of acute human herpesvirus 6 (HHV-6) infections. *J Clin Virol* **2011**; *52*:164–71.
43. Lanciotti RS, Kerst AJ, Nasci RS, et al. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. *J Clin Microbiol* **2000**; *38*:4066–71.
44. Tardei G, Ruta S, Chitu V, Rossi C, Tsai TF, Cernescu C. Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection. *J Clin Microbiol* **2000**; *38*: 2232–9.
45. Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. *Ann Neurol* **2006**; *60*:286–300.
46. Kapoor H, Signs K, Somsel P, Downes FP, Clark PA, Massey JP. Persistence of West Nile Virus (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease. *J Clin Virol* **2004**; *31*:289–91.
47. Prince HE, Tobler LH, Lapé-Nixon M, Foster GA, Stramer SL, Busch MP. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. *J Clin Microbiol* **2005**; *43*:4316–20.
48. Bitnun A, Ford-Jones EL, Petric M, et al. Acute childhood encephalitis and *Mycoplasma pneumoniae*. *Clin Infect Dis* **2001**; *32*:1674–84.
49. Domenech C, Leveque N, Lina B, Najjioullah F, Floret D. Role of *Mycoplasma pneumoniae* in pediatric encephalitis. *Eur J Clin Microbiol Infect Dis* **2009**; *28*:91–4.
50. Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for *Mycoplasma pneumoniae*-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the “gold standard”. *J Clin Microbiol* **2005**; *43*:2277–85.
51. Bitnun A, Richardson SE. *Mycoplasma pneumoniae*: Innocent Bystander or a True Cause of Central Nervous System Disease? *Curr Infect Dis Rep* **2010**; *12*:282–90.
52. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. *Brain* **2010**; *133*(Pt 6):1655–67.
53. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet Neurol* **2008**; *7*:1091–8.
54. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol* **2013**; *12*: 157–65.
55. Prüss H, Finke C, Hölte M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. *Ann Neurol* **2012**; *72*:902–11.
56. Graus F, Dalmau J. Paraneoplastic neurological syndromes. *Curr Opin Neurol* **2012**; *25*:795–801.
57. Chapman SJ, Hill AV. Human genetic susceptibility to infectious disease. *Nat Rev Genet* **2012**; *13*:175–88.
58. Reich DE, Lander ES. On the allelic spectrum of human disease. *Trends Genet* **2001**; *17*:502–10.
59. Choi M, Scholl UI, Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. *Proc Natl Acad Sci U S A* **2009**; *106*:19096–101.
60. Ng SB, Buckingham KJ, Lee C, et al. Exome sequencing identifies the cause of a Mendelian disorder. *Nat Genet* **2010**; *42*:30–5.
61. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. *Nat Rev Genet* **2008**; *9*:356–69.
62. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med* **2008**; *358*:568–79.
63. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* **2009**; *461*: 399–401.
64. Sancho-Shimizu V, Perez de Diego R, Jouanguy E, Zhang SY, Casanova JL. Inborn errors of anti-viral interferon immunity in humans. *Curr Opin Virol* **2011**; *1*:487–96.
65. Hollidge BS, González-Scarano F, Soldan SS. Arboviral encephalitis: transmission, emergence, and pathogenesis. *J Neuroimmune Pharmacol* **2010**; *5*:428–42.
66. Weaver SC, Reisen WK. Present and future arboviral threats. *Antiviral Res* **2010**; *85*:328–45.
67. Cleton N, Koopmans M, Reimerink J, Godeke GJ, Reusken C. Come fly with me: review of clinically important arboviruses for global travelers. *J Clin Virol* **2012**; *55*:191–203.
68. Heinz FX, Stiasny K, Holzmann H, et al. Vaccination and tick-borne encephalitis, central Europe. *Emerg Infect Dis* **2013**; *19*:69–76.
69. Centers for Disease Control and Prevention. West Nile virus disease and other arboviral diseases—United States, 2011. *MMWR Morb Mortal Wkly Rep* **2012**; *61*:510–4.
70. Arnold C. West Nile virus bites back. *Lancet Neurol* **2012**; *11*:1023–4.
71. Barzon L, Pacenti M, Franchin E, et al. Clinical and virological findings in the ongoing outbreak of West Nile virus Livenza strain in northern Italy, July to September 2012. *Euro Surveill* **2012**; *17*:20260.
72. Petersen LR, Fischer M. Unpredictable and difficult to control—the adolescence of West Nile virus. *N Engl J Med* **2012**; *367*:1281–4.
73. Public Health Agency of Canada: West Nile Virus MONITOR. <http://www.phac-aspc.gc.ca/wnv-vwn/mon-hmnsurv-eng.php> Accessed 27 June 2013.

74. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature* **2013**; 496:504–7.
75. Haddow AD, Odoi A. The incidence risk, clustering, and clinical presentation of La Crosse virus infections in the eastern United States, 2003–2007. *PLoS One* **2009**; 4:e6145.
76. Centers for Disease Control and Prevention. Human Jamestown canyon virus infection—Montana, 2009. *MMWR Morb Mortal Wkly Rep* **2011**; 60:652–5.
77. Suraweera W, Morris SK, Kumar R, et al. Deaths from symptomatically identifiable furious rabies in India: a nationally representative mortality survey. *PLoS Negl Trop Dis* **2012**; 6:e1847.
78. Rupprecht CE, Turmelle A, Kuzmin IV. A perspective on lyssavirus emergence and perpetuation. *Curr Opin Virol* **2011**; 1:662–70.
79. Kuzmin IV, Shi M, Orciari LA, et al. Molecular inferences suggest multiple host shifts of rabies viruses from bats to mesocarnivores in Arizona during 2001–2009. *PLoS Pathog* **2012**; 8:e1002786.
80. Feder HM, Petersen BW, Robertson KL, Rupprecht CE. Rabies: still a uniformly fatal disease? Historical occurrence, epidemiological trends, and paradigm shifts. *Curr Infect Dis Rep* **2012**; 14:408–22.
81. Gilbert AT, Petersen BW, Recuenco S, et al. Evidence of rabies virus exposure among humans in the Peruvian Amazon. *Am J Trop Med Hyg* **2012**; 87:206–15.
82. National Association of State Public Health Veterinarians Inc. Compendium of animal rabies prevention and control, 2011. *MMWR Recomm Rep* **2011**; 60(RR-6):1–17.
83. Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. *MMWR Recomm Rep* **2010**; 59(RR-2):1–9.
84. Wilde H, Wacharapluesadee S, Hemachudha T. Currently approved post-exposure rabies prophylaxis regimens. *Travel Med Infect Dis* **2012**; 10: 162–3.
85. Lembo T, Prevention PFR. The blueprint for rabies prevention and control: a novel operational toolkit for rabies elimination. *PLoS Negl Trop Dis* **2012**; 6:e1388.
86. Wu X, Smith TG, Rupprecht CE. From brain passage to cell adaptation: the road of human rabies vaccine development. *Expert Rev Vaccines* **2011**; 10:1597–608.
87. Jackson BR, Kucerova Z, Aguirre G, et al. Serologic survey of exposure following fatal *Balamuthia mandrillaris* infection—Southern Arizona, 2010. **2012**. Available at: <http://www.cdc.gov/EIS/downloads/2012.EIS.Conference.pdf>.
88. Schuster FL, Yagi S, Gavali S, et al. Under the radar: Balamuthia amoebic encephalitis. *Clin Infect Dis* **2009**; 48:879–87.
89. Prevention CfDca. Notes from the field: transplant-transmitted *Balamuthia mandrillaris*—Arizona, 2010. *MMWR Morb Mortal Wkly Rep* **2010**; 59:1182.
90. Centers for Disease C, Prevention. *Balamuthia mandrillaris* transmitted through organ transplantation—Mississippi, 2009. *MMWR Morb Mortal Wkly Rep* **2010**; 59:1165–70.